Literature DB >> 15920322

Variceal bleeding: pharmacological therapy.

Jaime Bosch1, Juan G Abraldes.   

Abstract

The complications of portal hypertension are totally prevented if hepatic venous pressure gradient is decreased below 12 mm Hg. Besides, if this target is not achieved, a 20% decrease in portal pressure from baseline levels offers an almost total protection from variceal bleeding. This sets the rationale for drug therapy to reduce portal pressure in portal hypertension. Pharmacological therapy to decrease portal pressure includes vasoconstrictors to decrease portal blood inflow, vasodilators to decrease hepatic resistance, and combination therapy. Oral agents, such as beta-adrenergic blockers and organic nitrates, are used for long-term prevention of variceal bleeding, while parenteral agents, such as somatostatin (and analogues) and terlipressin, are used for the treatment of acute variceal bleeding. 2005 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920322     DOI: 10.1159/000084722

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  5 in total

1.  Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk patients on anticoagulation therapy.

Authors:  J Molina-Infante; B Perez-Gallardo; G Gonzalez-Garcia; M Fernandez-Bermejo; J M Mateos-Rodriguez; P Robledo-Andres
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

Review 2.  Emergency management of bleeding esophageal varices: drugs, bands or sleep?

Authors:  Brian M Yan; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

3.  Esophageal Capsule Endoscopy for Screening Esophageal Varices among Japanese Patients with Liver Cirrhosis.

Authors:  Haruya Ishiguro; Shoichi Saito; Hiroo Imazu; Hiroyuki Aihara; Tomohiro Kato; Hisao Tajiri
Journal:  Gastroenterol Res Pract       Date:  2011-11-30       Impact factor: 2.260

4.  Revision and update on clinical practice guideline for liver cirrhosis.

Authors:  Ki Tae Suk; Soon Koo Baik; Jung Hwan Yoon; Jae Youn Cheong; Yong Han Paik; Chang Hyeong Lee; Young Seok Kim; Jin Woo Lee; Dong Joon Kim; Sung Won Cho; Seong Gyu Hwang; Joo Hyun Sohn; Moon Young Kim; Young Bae Kim; Jae Geun Kim; Yong Kyun Cho; Moon Seok Choi; Hyung Joon Kim; Hyun Woong Lee; Seung Up Kim; Ja Kyung Kim; Jin Young Choi; Dae Won Jun; Won Young Tak; Byung Seok Lee; Byoung Kuk Jang; Woo Jin Chung; Hong Soo Kim; Jae Young Jang; Soung Won Jeong; Sang Gyune Kim; Oh Sang Kwon; Young Kul Jung; Won Hyeok Choe; June Sung Lee; In Hee Kim; Jae Jun Shim; Gab Jin Cheon; Si Hyun Bae; Yeon Seok Seo; Dae Hee Choi; Se Jin Jang
Journal:  Korean J Hepatol       Date:  2012-03-22

5.  Octreotide attenuates liver fibrosis by inhibiting hepatic heme oxygenase-1 expression.

Authors:  Shi-Bin Guo; Qing Li; Zhi-Jun Duan; Qiu-Ming Wang; Qin Zhou; Xiao-Yu Sun
Journal:  Mol Med Rep       Date:  2014-10-22       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.